AtriCure, Inc. (NASDAQ:ATRC – Get Free Report) has been given an average recommendation of “Buy” by the four analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued ratings on the stock in the last […]
Advisors Capital Management LLC lifted its position in shares of AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 25.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,208 shares of the medical device company’s stock after acquiring an additional 11,529 shares during the […]
AtriCure (NASDAQ:ATRC – Free Report) had its price objective increased by Piper Sandler from $55.00 to $65.00 in a research note published on Wednesday morning, FlyOnTheWall reports. ATRC has been the subject of several other research reports. Needham & Company LLC upped their target price on shares of AtriCure from $60.00 to $68.00 and gave […]
Emerald Mutual Fund Advisers Trust raised its position in AtriCure, Inc. (NASDAQ:ATRC – Free Report) by 1.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 411,400 shares of the medical device company’s stock after purchasing an additional 5,700 shares during […]
AtriCure (NASDAQ:ATRC – Get Free Report) announced its quarterly earnings results on Tuesday. The medical device company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.15, Briefing.com reports. The firm had revenue of $100.92 million during the quarter, compared to analysts’ expectations of $97.55 million. AtriCure had a negative net […]